- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01842542
Efficacy and Safety Study of NeuroStar TMS Therapy in Patients With Major Depressive Disorder With Postpartum Onset
An Open-Label Study to Evaluate the Efficacy and Safety of the Neuronetics NeuroStar TMS Therapy System in Patients With Major Depressive Disorder (MDD) With Postpartum Onset.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Evaluate the antidepressant effectiveness of acute treatment with NeuroStar TMS Therapy in patients with MDD with postpartum onset.
Determine the safety of NeuroStar TMS Therapy by assessment of any medically significant, device-related adverse events during acute treatment.
Determine the Safety of NeuroStar TMS Therapy by assessment of maternal and infant interactions on standardized bonding questionnaires.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Connecticut
-
Hartford, Connecticut, United States, 06102
- Hartford Hospital Institute of Living
-
-
Florida
-
Gainesville, Florida, United States, 32606
- UF Health Adult Psychiatry - Springhill
-
Pensacola, Florida, United States, 32502
- Harmonex Neuroscience and Research of Pensacola
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
-
Kentucky
-
Louisville, Kentucky, United States, 40222
- Integrative Psychiatry
-
-
New York
-
New York, New York, United States, 10022
- TMS Medical Associates of NY
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18104
- TMS Center of Lehigh Valley
-
-
Utah
-
Salt Lake City, Utah, United States, 84108
- University of Utah - Neuropsychiatric Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female outpatients, 18 to 50 years of age.
- Diagnosis of DSM-IV defined Major Depressive Disorder, single or recurrent episode, with current episode duration of at least 2 weeks.
- Onset and duration of current illness within 6 months of live childbirth.
- HAMD17 total score of greater than or equal to 18 and a score on the Edinburgh Postnatal Depression scale (EPDS) greater than or equal to 10.
- Patient cannot be on an antidepressant or other psychotropic medications during the study.
- Capable and willing to provide informed consent.
- Signed HIPAA authorization.
- Able to adhere to the treatment schedule.
Exclusion Criteria:
- Individuals diagnosed by the Investigator with the following conditions (current unless otherwise stated): Depression secondary to a general medical condition, or substance-induced Seasonal pattern of depression as defined by DSM-IV;History of substance abuse or dependence within the past year(except nicotine and caffeine);Any psychotic disorder (lifetime), including schizoaffective disorder, or major depression with psychotic features in this or previous episodes;Bipolar disorder;Eating disorder (current or within the past year);Obsessive compulsive disorder (lifetime); or Post-traumatic stress disorder (current or within the past year).
- Individuals with a clinically defined neurological disorder or insult including, but not limited to:Any condition likely to be associated with increased intracranial pressure;Space occupying brain lesion;History of cerebrovascular accident;Transient ischemic attack within two years; Cerebral aneurysm; Dementia;Parkinson's disease;Huntington's chorea;Multiple sclerosis.
- History of treatment with Vagus Nerve Stimulation.
- History of failure to respond to an adequate course of ECT treatment.
- Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease.
- Intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed.
- Women of child-bearing potential not using a medically accepted form of contraception when engaging in sexual intercourse.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Transcranial Magnetic Stimulation (TMS)
Patients will receive NeuroStar Transcranial Magnetic Stimulation (TMS) therapy treatments 5 times a week for up to 8 weeks during the acute phase, 3 times during the first week, 2 times during the second week and 1 time during the third week of the taper phase. Efficacy Assessments will be conducted throughout the acute and taper phase at protocol specific timepoints. |
Acute phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, five times weekly for up to 8 weeks. 3 week taper phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, 3 times during the first week, 2 times during the second week and one time during the third week. In addition to treatments, patients may receive treatment as usual at the direction of their treating physician.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the antidepressant effectiveness of acute treatment with NeuroStar TMS Therapy in patients with MDD with postpartum onset
Time Frame: up to 8 weeks.
|
Acute NeuroStar TMS treatment of 5 days per week for upto 8 weeks.
|
up to 8 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine the safety of NeuroStar TMS Therapy.
Time Frame: upto 8 weeks plus 3 week taper.
|
Medically significant, device related adverse events will be collected during the acute and taper phase.
|
upto 8 weeks plus 3 week taper.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine the safety of NeuroStar TMS Therapy by assessment of maternal and infant interactions on standardized bonding questionnaires.
Time Frame: Up to 8 weeks plus 3 week taper.
|
Patients complete questionnaires during the acute and taper treatment phase at protocol specific timepoints.
|
Up to 8 weeks plus 3 week taper.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: David Brock, MD, Neuronetics, Inc.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 44-03014-000
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression, Postpartum
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Women's Health Research Institute...CompletedPostpartum Depression | Perinatal Disorder | Postpartum Disorder | Perinatal Depression | Postpartum Anxiety | Postnatal DepressionCanada
-
University of CoimbraEnrolling by invitationPostPartum DepressionPortugal
-
University of MinnesotaNational Institute of Mental Health (NIMH)Completed
-
Sage TherapeuticsCompletedSevere Postpartum DepressionUnited States
-
Women's College HospitalCanadian Institutes of Health Research (CIHR); Michael Garron HospitalCompletedPostpartum Depression | Postpartum Anxiety | Postpartum Blues | Postpartum Mood DisorderCanada
-
Gazi UniversityCompletedPostpartum Depression | Postpartum AdaptationTurkey
-
British Columbia Children's HospitalActive, not recruiting
-
University of RochesterMae Stone Goode FoundationCompletedPostpartum Depression | Postpartum AnxietyUnited States
-
Hacettepe UniversityCompletedQuality of Life | Postpartum Depression | Nursing Caries | Nurse's Role | Postpartum Disorder | Postpartum AnxietyTurkey
Clinical Trials on NeuroStar Transcranial Magnetic Stimulation (TMS)
-
NeuroneticsUnknownMajor Depressive DisorderUnited States
-
Sheppard Pratt Health SystemMayo ClinicCompleted
-
Butler HospitalNeuronetics; Providence VA Medical CenterCompletedMajor Depressive Disorder | Posttraumatic Stress Disorder | Transcranial Magnetic Stimulation, RepetitiveUnited States
-
University of MichiganNational Institute of Mental Health (NIMH); NeuroneticsCompleted
-
Northwestern UniversityNeuroneticsCompletedDepression | Anxiety | Cancer in Remission (Any Type or Stage)United States
-
NeuroneticsWithdrawnMajor Depressive DisorderUnited Kingdom
-
Paul E. CroarkinCompletedMajor Depressive DisorderUnited States
-
Emory UniversityNational Institute of Mental Health (NIMH)Recruiting
-
Hartford HospitalNeuroneticsCompleted
-
Centre Hospitalier St AnneNot yet recruitingTreatment Resistant Schizophrenia